Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Matthew I. Milstein"'
Autor:
David J. Kwiatkowski, Gopa Iyer, Martin H. Voss, James J. Harding, Hebert A. Vargas, Geoffrey I. Shapiro, Anne Sisk, David M. Hyman, Junko Tsuji, Lynette M. Sholl, Katherine E. Kargus, Jennifer Hedglin, Matthew I. Milstein, Ketki Bhushan, Solida Pruitt-Thompson, Khanh T. Do, Krinio Giannikou, Katarzyna Klonowska, Elio Adib
Table S3. Toxicities (any level) occurring in at least two patients, grouped by CTCAE v4.0 categories. For patients with more than one adverse event per category, only the highest-grade event was counted.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43be27b2858b437996e4d0c2a2f5fd63
https://doi.org/10.1158/1078-0432.22480322
https://doi.org/10.1158/1078-0432.22480322
Autor:
David J. Kwiatkowski, Gopa Iyer, Martin H. Voss, James J. Harding, Hebert A. Vargas, Geoffrey I. Shapiro, Anne Sisk, David M. Hyman, Junko Tsuji, Lynette M. Sholl, Katherine E. Kargus, Jennifer Hedglin, Matthew I. Milstein, Ketki Bhushan, Solida Pruitt-Thompson, Khanh T. Do, Krinio Giannikou, Katarzyna Klonowska, Elio Adib
Supplementary Methods File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ef00fe45b9ce87b96632e809265c98
https://doi.org/10.1158/1078-0432.22480331.v1
https://doi.org/10.1158/1078-0432.22480331.v1
Autor:
David J. Kwiatkowski, Gopa Iyer, Martin H. Voss, James J. Harding, Hebert A. Vargas, Geoffrey I. Shapiro, Anne Sisk, David M. Hyman, Junko Tsuji, Lynette M. Sholl, Katherine E. Kargus, Jennifer Hedglin, Matthew I. Milstein, Ketki Bhushan, Solida Pruitt-Thompson, Khanh T. Do, Krinio Giannikou, Katarzyna Klonowska, Elio Adib
Purpose:This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations.Patients and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aa0191ff343379a0a91c7adc522313e
https://doi.org/10.1158/1078-0432.c.6530420
https://doi.org/10.1158/1078-0432.c.6530420
Autor:
David J. Kwiatkowski, Gopa Iyer, Martin H. Voss, James J. Harding, Hebert A. Vargas, Geoffrey I. Shapiro, Anne Sisk, David M. Hyman, Junko Tsuji, Lynette M. Sholl, Katherine E. Kargus, Jennifer Hedglin, Matthew I. Milstein, Ketki Bhushan, Solida Pruitt-Thompson, Khanh T. Do, Krinio Giannikou, Katarzyna Klonowska, Elio Adib
Fig S1. A. Treatment duration and clinical events for four subjects with clinical benefit. In the swimmer plot, patients are deceased at last follow-up unless indicated by the arrowhead. Abbreviations: LMS - leiomyosarcoma; UTUC - upper tract urothel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d8464361a2c1a3d8c397bee672c8ea
https://doi.org/10.1158/1078-0432.22480337
https://doi.org/10.1158/1078-0432.22480337
Autor:
David M. Hyman, Lynette M. Sholl, Katherine Kargus, Hebert Alberto Vargas, Ann E. Sisk, Elio Adib, James J. Harding, Solida Pruitt-Thompson, Krinio Giannikou, Jennifer Hedglin, Martin H. Voss, Khanh T. Do, Ketki Bhushan, Matthew I. Milstein, David J. Kwiatkowski, Gopa Iyer, Geoffrey I. Shapiro, Junko Tsuji, Katarzyna Klonowska
Publikováno v:
Clinical Cancer Research. 27:3845-3853
Purpose:This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations.Patients and M
Autor:
Marcus O Butler, Osamu Imataki, Yoshihiro Yamashita, Makito Tanaka, Sascha Ansén, Alla Berezovskaya, Genita Metzler, Matthew I Milstein, Mary M Mooney, Andrew P Murray, Hiroyuki Mano, Lee M Nadler, Naoto Hirano
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30229 (2012)
Using in vivo mouse models, the mechanisms of CD4+ T cell help have been intensively investigated. However, a mechanistic analysis of human CD4+ T cell help is largely lacking. Our goal was to elucidate the mechanisms of human CD4+ T cell help of CD8
Externí odkaz:
https://doaj.org/article/ecfdc6166ac84d34b817552f4d642e0d
Autor:
Matthew I. Milstein, Naoto Hirano, Makito Tanaka, Osamu Imataki, Alla Berezovskaya, Sascha Ansén, Lee M. Nadler, Kiyotaka Kuzushima, Marcus O. Butler
Publikováno v:
The Journal of Immunology. 188:1609-1619
Although both MHC class II/CD8α double-knockout and CD8β null mice show a defect in the development of MHC class I-restricted CD8+ T cells in the thymus, they possess low numbers of high-avidity peripheral CTL with limited clonality and are able to
Autor:
Makito Tanaka, Naoto Hirano, Marcus O. Butler, Alla Berezovskaya, Matthew I. Milstein, Sascha Ansén, Osamu Imataki, Lee M. Nadler, Genita Metzler, Mary M. Mooney
Publikováno v:
International Immunology. 22:863-873
Many preclinical experiments have attested to the critical role of CD4(+) T cell help in CD8(+) cytotoxic T lymphocyte (CTL)-mediated immunity. Recent clinical trials have demonstrated that reinfusion of CD4(+) T cells can induce responses in infecti
Autor:
Philip Friedlander, Kristen E. Stevenson, F. Stephen Hodi, Sara Russell, Alla Berezovskaya, Elsa F. Velazquez, Michael T. Jaklitsch, Marisa Flavin, Genita Metzler, Osamu Imataki, Martin C. Mihm, Marcus O. Butler, Donna Neuberg, Lee M. Nadler, Donald P. Lawrence, Naoto Hirano, Mary M. Mooney, Makito Tanaka, Andrew P. Murray, Matthew I. Milstein, Linda Drury, Lisa L. Brennan
Publikováno v:
Science translational medicine. 3(80)
While advanced stage melanoma patients have a median survival of less than a year, adoptive T cell therapy can induce durable clinical responses in some patients. Successful adoptive T cell therapy to treat cancer requires engraftment of anti-tumor T
Autor:
Makito Tanaka, Osamu Imataki, Genita Metzler, Marcus O. Butler, Sascha Ansén, Matthew I. Milstein, Lee M. Nadler, Mary M. Mooney, Hiroyuki Mano, Yoshihiro Yamashita, Naoto Hirano, Alla Berezovskaya, Andrew P. Murray
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30229 (2012)
PLoS ONE
PLoS ONE
Background Using in vivo mouse models, the mechanisms of CD4+ T cell help have been intensively investigated. However, a mechanistic analysis of human CD4+ T cell help is largely lacking. Our goal was to elucidate the mechanisms of human CD4+ T cell